Anebulo Pharmaceuticals, Inc. logo

Anebulo Pharmaceuticals, Inc.

0001815974

Anebulo is developing innovative therapies for substance use disorders, particularly cannabinoid intoxication. They focus on evidence-based medicine to drive clinical and behavioral change, aiming to improve the lives of patients struggling with addiction. The company prioritizes the development of Selonabant for unintentional cannabis poisoning in children.

83
Très Fiable
Score de Confiance

Registre Officiel

Dénomination Sociale
Anebulo Pharmaceuticals, Inc.
Numéro d'organisation
0001815974
Numéro de TVA
851170950
Statut de l'Entreprise
Active
Adresse
C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX 78734
Codes d'Activité
Pharmaceutical Preparations, 2834

Dernière vérification: 1/2/2026

Analyse Qualité IA

Industrie
Biotechnology
SSL/HTTPS
Sécurisé
E-mail professionnel
Oui
E-mail de contact
info@anebulo.com

🌟 Entreprises similaires de confiance

vTv Therapeutics Inc.

vTv Therapeutics Inc. logo
89/100 · Très Fiable

vTv Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of diabetes patients. They focus on developing oral, small molecule drug candidates. Their lead candidate is cadisegliatin, a potential adjunctive therapy to insulin for type 1 diabetes. They are also exploring indications for type 2 diabetes and other chronic conditions.

3980 PREMIER DR, États-Unis
Voir le profil

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. logo
86/100 · Très Fiable

Bolt Biotherapeutics is a clinical-stage biotech company working to harness the power of the immune system to improve lives and eradicate cancer. The company is developing novel immunotherapies using foreign patterns to trigger the innate immune system, which teaches the immune system to recognize and kill cancer. Bolt was founded in 2015.

900 CHESAPEAKE DRIVE, États-Unis
Voir le profil

IOVANCE BIOTHERAPEUTICS, INC.

IOVANCE BIOTHERAPEUTICS, INC. logo
86/100 · Très Fiable

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. They are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors.

825 INDUSTRIAL ROAD, États-Unis
Voir le profil